Abstract
The intravenous administration of Bleomycin to 10 dogs at different dosages resulted in varying degrees of interstitial pneumonia in all cases and a lower incidence of nephrosis, foot pad excoriation and ulceration, onychoptosis, and alopecia. Pulmonary changes did not occur as a simple dose-related phenomenon. The lesions required at least 38 days to become apparent and appeared to increase in severity with time. Even at the lowest dose used (0·625 mg/kg body weight) very severe changes were seen 128 days after cessation of therapy. Morphological features of interstitial pneumonia were subpleural localization, focal mesothelial hyperplasia, marked hyperplasia and metaplasia of type II pneumocytes, fetalization of alveoli, and a pleomorphic inflammatory infiltrate. In cross-sections of lung lobes selected for histology approximately 1 to 22% of the parenchyma contained lesions. Involved areas showed marked elastosis, excess of reticular fibres, fibrosis, and increased acid mucopolysaccharides. The administration of Bleomycin produced pulmonary changes similar in many respects to those reported in busulphan-treated patients and desquamative interstitial pneumonia. The finding of interstitial pneumonia and pulmonary fibrosis in dogs treated with low doses over prolonged periods points the need to monitor pulmonary function in humans treated with Bleomycin.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brewer D. B., Heath D., Asquith P. Electron microscopy of desquamative interstitial pneumonia. J Pathol. 1969 Feb;97(2):317–323. doi: 10.1002/path.1710970217. [DOI] [PubMed] [Google Scholar]
- Ichikawa T., Matsuda A., Miyamoto K., Tsubosaki M., Umezawa H. Biological studies on bleomycin A. J Antibiot (Tokyo) 1967 Jul;20(3):149–155. [PubMed] [Google Scholar]
- Ichikawa T., Nakano I., Hirokawa I. Bleomycin treatment of the tumors of penis and scrotum. J Urol. 1969 Dec;102(6):699–707. doi: 10.1016/s0022-5347(17)62235-3. [DOI] [PubMed] [Google Scholar]
- Ishizuka M., Takayama H., Takeuchi T., Umezawa H. Activity and toxicity of bleomycin. J Antibiot (Tokyo) 1967 Jan;20(1):15–24. [PubMed] [Google Scholar]
- LEAKE E., SMITH W. G. DIFFUSE INTERSTITIAL PULMONARY FIBROSIS AFTER BUSULPHAN THERAPY. Lancet. 1963 Aug 31;2(7305):432–434. doi: 10.1016/s0140-6736(63)92173-1. [DOI] [PubMed] [Google Scholar]
- LIEBOW A. A., STEER A., BILLINGSLEY J. G. DESQUAMATIVE INTERSTITIAL PNEUMONIA. Am J Med. 1965 Sep;39:369–404. doi: 10.1016/0002-9343(65)90206-8. [DOI] [PubMed] [Google Scholar]
- Littler W. A., Kay J. M., Hasleton P. S., Heath D. Busulphan lung. Thorax. 1969 Nov;24(6):639–655. doi: 10.1136/thx.24.6.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- OLINER H., SCHWARTZ R., RUBIO F., DAMESHEK W. Interstitial pulmonary fibrosis following busulfan therapy. Am J Med. 1961 Jul;31:134–139. doi: 10.1016/0002-9343(61)90229-7. [DOI] [PubMed] [Google Scholar]
- Umezawa H. Bleomycin and other antitumor antibiotics of high molecular weight. Antimicrob Agents Chemother (Bethesda) 1965;5:1079–1085. [PubMed] [Google Scholar]
- Umezawa H., Ishizuka M., Maeda K., Takeuchi T. Studies on bleomycin. Cancer. 1967 May;20(5):891–895. doi: 10.1002/1097-0142(1967)20:5<891::aid-cncr2820200550>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
- Umezawa H., Maeda K., Takeuchi T., Okami Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 1966 Sep;19(5):200–209. [PubMed] [Google Scholar]